Clinical Trials Browser

Terminated × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Tacrolimus × Clear all

Immune System Diseases, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT01135329 2018-07-03

Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

Phase 2 Terminated

15 enrolled 8 charts

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02877082 2018-04-30

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

Phase 2 Terminated

5 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Primary Myelofibrosis

NCT01621477 2017-02-20

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

Phase 2 Terminated

34 enrolled 12 charts

LymphoidMyeloidOther hematologic neoplasmSarcoma

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT00579111 2016-05-04

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Phase 1/2 Terminated

4 enrolled 8 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoproliferative Disorders, Multiple Myeloma, Myeloproliferative Disorders, Paraproteinemias, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00499889 2012-04-23

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

Phase 2 Terminated

42 enrolled 8 charts

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Clinical Trials

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients